

RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/080,013
Filing Date	19 February 2002
First Named Inventor	MORIARTY
Group-Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	ORT-1557

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
KAL		US 5,314,813	A	Peterson et al.	05-14-1994	
		US 5,487,974	A	Boon Falleur et al.,	01-30-1996	
		US 5,529,921	A	Peterson et al.	06-25-1996	
		US 5,662,907	A	Kubo et al.	09-02-1997	
		US 5,759,783	A	Lurquin et al.	06-02-1998	
		US 5,843,648	A	Robbins et al.	12-01-1998	
		US 5,844,075	A	Kawakami et al.	12-01-1998	
		US 5,874,560	A	Kawakami et al.	02-23-1999	
		US 5,994,523	A	Kawakami et al.	11-30-1999	
		US 6,075,122	A	Cheever et al.	06-13-2000	
		US 6,140,050	A	Sahin et al.	10-31-2000	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner's Initials <sup>6</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KAL		ALLISON et al., "Manipulation of Co-Stimulatory Signals to Enhance Anti-Tumor T-Cells Responses", <i>Curr. Op. Immunol.</i> (1995) 7(5):682-686.	
		BABCOCK et al., "Ovarian and Breast Cytotoxic T Lymphocytes Can Recognize Peptides from the Amino Enhancer of Split Protein of the Notch Complex", <i>Mol. Immunol.</i> (1998) 35(17): 1121-1133.	
		BAKKER et al., "Melanocyte-Lineage-Specific Antigen gp100 is Recognized by Melanoma-Derived Tumor-Infiltrating Lymphocytes", <i>J. Exp. Med.</i> (1994) 179(3):1005-1009.	
		BRICHARD et al., "The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas", <i>J. Exp. Med.</i> (1993) 178(2):489-495.	
		BROSSART et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <i>Blood</i> (1999) 93(12): 4309-4317.	
		CAI et al., "Transfected <i>Drosophila</i> Cells as a Probe for Defining the Minimal Requirements for Stimulating Unprimed CD8 <sup>+</sup> T Cells", <i>P. N. A. S. USA</i> (1996) 93(25):14736-14741.	
		CHEN et al., "Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL", <i>J. Immunology</i> (2000) 165(2): 948-955.	

Examiner Signature	<i>Harun A. Ganiella</i>	Date Considered	5/16/2004
-----------------------	--------------------------	--------------------	-----------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/080,013
Filing Date	19 February 2002
First Named Inventor	MORIARTY
Group Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	ORT-1557

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KAL		FISK et al., "Identification of an Immunodominant Peptide of HER-2/neu Proto-oncogene Recognized by Ovarian Tumor-Specific Cytotoxic T Lymphocyte Lines", <i>J. Exp. Med.</i> (1995) 181(6): 2109-2117.	
		GAUGLER et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes", <i>J. Exp. Med.</i> (1994) 179(3):921-930.	
		GUELLY, C., et al., "Activation Requirements of Circulating Antigen-Specific Human CD8+Memory T Cells Probed With Insect Cell-Based Artificial Antigen-Presenting Cells", <i>Eur. J. Immunol.</i> , January 2002, pp. 182-192; Vol. 32	
		KAWAKAMI et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restricted Tumor Infiltrating Lymphocytes", <i>J. Exp. Med.</i> (1994) 180(1):347-352.	
		KAWAKAMI et al., "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression", <i>J. Immunol.</i> (1995) 154(8):3961-3968.	
		KAWASHIMA et al., "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors", <i>Human Immunology</i> (1998) 59: 1-14.	
		KIM et al., "Folate Binding Protein Peptide 191-199 Presented on Dendritic Cells Can Stimulate CTL from Ovarian and Breast Cancer Patients", <i>Anticancer Res.</i> (1999) 19(4B): 2907-2916.	
		LATOUCHE, JEAN-BAPISTE and SADELAIN, MICHEL "Induction of Human Cytotoxic T Lymphocytes by Artificial Antigen-Presenting Cells", <i>Nature Biotech</i> (2000) 18:405-409.	
		RICHARDS et al., "Therapeutic and Immunologic Evaluation of Autologous CTL Generated Using Transgenic Drosophila Cells as APC's for the Treatment of Melanoma", <i>Amer. Soc. Clin. Oncol.</i> (Display: May, 2001), 20(1 of 2): Abstract 1015, pg. 254a.	
		ROBBINS et al., "Recognition of Tyrosinase by Tumor-Infiltrating Lymphocytes from a Patient Responding to Immunotherapy", <i>Cancer Res.</i> (1994) 54: 3124-3126.	
		SCHNEIDER, IMOGENE "Differentiation of Larval Drosophila Eye-Antennal Discs in Vitro", <i>Exp. Zool.</i> (1964) 156(1):91-104.	
		SCHULTZE, J. L. et al., "Autologous Tumor Infiltrating T Cells Cytotoxic For Follicular Lymphoma Cells Can Be Expanded In Vitro", <i>Blood</i> ; May 1997, pp. 3806-3816; Vol. 89, No. 10	
		SKIPPER et al., "An HLA-A2-Restricted Tyrosinase Antigen on Melanoma Cells Results from Post Translations Modification and Suggests a Novel Pathway for Processing of Membrane Proteins", <i>J. Exp. Med.</i> (1996) 183(2):527-534.	
		STIMPFL et al., "Expression of Mucins and Cytokeratins in Ovarian Cancer Cell Lines", <i>Cancer Letters</i> (1999) 145(1-2): 133-141.	
		SUN et al., "Dual Function of Drosophila Cells as APL for Naïve CD8+ T Cells: Implications for Tumor Immunotherapy", <i>Immunity</i> (1996) 4(6):555-564.	
		VISSERS et al., "The Renal Cell Carcinoma-Associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-Restricted Epitope Recognized by Cytotoxic T Lymphocytes", <i>Cancer Res.</i> (1999);59(21): 5554-5559.	
		VONDERHEIDE et al., "Equivalent Induction of Telomerase-Specific Cytotoxic T Lymphocytes from Tumor-Bearing Patients and Healthy Individuals", <i>Cancer Res.</i> (2001) 61(23): 8366-8370.	

Examiner Signature	<i>Karin D. Gaudin</i>	Date Considered	5/16/2004
--------------------	------------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OCT 21 2002

TECH CENTER 1000/2900



Page 1 of 1

<b>Application Number</b>	10/080,013
<b>Filing Date</b>	19 February 2002
<b>First Named Inventor</b>	MORIARTY
<b>Group Art Unit</b>	Not Assigned
<b>Examiner Name</b>	Not Assigned
<b>Attorney Docket Number</b>	ORT-1557

[illegible][illegible][illegible]

Examiner Signature	<i>James D. Canella</i>	Date Considered	5/16/2004
-----------------------	-------------------------	--------------------	-----------